IRD Insider Trading Activity and SEC Form 4 Filings
IRD insider trading summary
Over the past 12 months, insiders at Opus Genetics, Inc. (IRD) reported 17 sales worth $38.1M by 8 insiders and 2 open-market purchases worth $324K by 1 insider on SEC Form 4. Net insider selling was $37.8M.
Latest IRD insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 3, 2026 | George Magrath | Chief Executive Officer | Sell | $110K (28,258 @ $3.90) |
| Oct 23, 2026 | Benjamin R Yerxa | President | Sell | $90K (25,520 @ $3.53) |
| Oct 23, 2026 | Robert E. Gagnon | Chief Financial Officer | Sell | $50K (14,000 @ $3.55) |
| Oct 23, 2026 | Joseph K Schachle | Chief Operating Officer | Sell | $17K (4,767 @ $3.56) |
| Oct 23, 2026 | George Magrath | Chief Executive Officer | Sell | $34K (9,591 @ $3.58) |
| Oct 23, 2026 | Benjamin R Yerxa | President | Sell | $27K (7,669 @ $3.55) |
| Sep 30, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Sell | $2.8M (556,000 @ $4.96) |
| Sep 30, 2026 | Foundation Fighting Blindness, Inc. | Director | Sell | $2.8M (556,000 @ $4.96) |
| Sep 3, 2026 | Robert E. Gagnon | Chief Financial Officer | Sell | $127K (28,000 @ $4.54) |
| May 18, 2026 | Foundation Fighting Blindness, Inc. | Director | Sell | $7.4M (1,700,000 @ $4.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.